A Phase 2 Randomised, Double-blind, Placebo-controlled Study of the Effects of VIA-2291, a 5-lipoxygenase Inhibitor, on Atherosclerotic Plaque and Biomarkers of Vascular Inflammation in Patients with Carotid Stenosis Undergoing Elective Carotid Endarterectomy.

Registry ID

EUCTR2006-001635-21

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

VIA PHARMACEUTICALS, INC.

Start date

2006-12-21

Last update

2026-08-16

Conditions

• Carotid Stenosis.

Summary

Evaluate the effect of VIA-2291 100mg relative to placebo on ex vivo plaque leukotriene B4 LTB4 concentrations and changes from baseline in ex vivo LTB4 synthesis in whole blood in patients with carotid artery stenosis after 12 weeks of daily dosing.

Locations

• , , Italy

View on source registry